Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
James MG Larkin & Stanley B Kaye. (2006) Epothilones in the treatment of cancer. Expert Opinion on Investigational Drugs 15:6, pages 691-702.
Read now
Read now
Petra Reinecke, Michael Schmitz, E. Marion Schneider, Helmut Erich Gabbed & Claus-Dieter Gerharz. (2000) Multidrug Resistance Phenotype and Paclitaxel (Taxol®) Sensitivity in Human Renal Carcinoma Cell Lines of Different Histologic Types. Cancer Investigation 18:7, pages 614-625.
Read now
Read now
M. T. Huizing, V. H. Sewberath Misser, R. C. Pieters, W. W. ten Bokkel Huinink, C. H. N. Veenhof, J. B. Vermorken, H. M. Pinedo & J. H. Beijnen. (1995) Taxanes: A New Class of Antitumor Agents. Cancer Investigation 13:4, pages 381-404.
Read now
Read now
Articles from other publishers (36)
Surinder M. Soond, Lyudmila V. Savvateeva, Vladimir A. Makarov, Neonila V. Gorokhovets, Paul A. Townsend & Andrey A. ZamyatninJr.Jr.. (2021) Cathepsin S Cleaves BAX as a Novel and Therapeutically Important Regulatory Mechanism for Apoptosis. Pharmaceutics 13:3, pages 339.
Crossref
Crossref
Smriti Samanta, Suvranil Ghosh & Narayan Chandra Mandal. 2021. Endophytes. Endophytes
103
151
.
E. Diamond, A.M. Molina, M. Carbonaro, N.H. Akhtar, P. Giannakakou, S.T. Tagawa & D.M. Nanus. (2015) Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy. Critical Reviews in Oncology/Hematology 96:3, pages 518-526.
Crossref
Crossref
Hui Huang, Michael Menefee, Maureen Edgerly, Sen Zhuang, Herb Kotz, Marianne Poruchynsky, Lyn Mickley Huff, Susan Bates & Tito Fojo. (2010) A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research 16:5, pages 1634-1641.
Crossref
Crossref
Walter M. Stadler. 2008. Renal Cell Cancer. Renal Cell Cancer
467
474
.
James O. Jin & Walter M. Stadler. 2008. Clinical Management of Renal Tumors. Clinical Management of Renal Tumors
385
397
.
J.M.G. Larkin & S.B. Kaye. (2007) Potential clinical applications of epothilones: a review of phase II studies. Annals of Oncology 18, pages v28-v34.
Crossref
Crossref
Axel Walther, David Chao & Martin Gore. 2007. Clinical Progress in Renal Cancer. Clinical Progress in Renal Cancer
153
166
.
U. Keilholz & J. Beck. 2007. Therapiekonzepte Onkologie. Therapiekonzepte Onkologie
1031
1050
.
Lee M. Greenberger & Deepak Sampath. 2006. Cancer Drug Resistance. Cancer Drug Resistance
329
358
.
Christine Odoux & Andreas Albers. 2004. TRAIL (TNF-Related Apoptosis-Inducing Ligand). TRAIL (TNF-Related Apoptosis-Inducing Ligand)
385
407
.
Wolfgang Hiddemann, Heinz Huber & Claus R. BartramW. E. Aulitzky, J. Beck & C. Huber. 2004. Die Onkologie. Die Onkologie
1181
1201
.
. (2003) Pharmacokinetic Interaction between Diltiazem and Paclitaxel in Rats. Journal of Korean Pharmaceutical Sciences 33:4, pages 299-304.
Crossref
Crossref
Ulka Vaishampayan. (2003) A Review of Current and Future Treatment Options in Renal Cancer. American Journal of Cancer 2:3, pages 201-210.
Crossref
Crossref
Christopher M. George & Walter M. Stadler. 2003. Kidney Cancer. Kidney Cancer
173
182
.
Wolfgang Wrasidlo, Andreas Niethammer, Serdar Deger, Jalid Sehouli, Andreas Kulozik, Wilhelm Geilen, Günter Henze, Gerhard Gaedicke & Holger N. Lode. (2002) Pilot study of hydrolytically activated paclitaxel prodrug therapy in patients with progressive malignancies. Current Therapeutic Research 63:4, pages 247-262.
Crossref
Crossref
Jared A Gollob, Melissa P Upton, William C DeWolf & Michael B Atkins. (2001) Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. Urology 58:6, pages 1058.
Crossref
Crossref
Ulka Vaishampayan, Lawrence Flaherty, Wei Du & Maha Hussain. (2001)
Phase II evaluation of paclitaxel, α‐interferon, and
cis
‐retinoic acid in advanced renal cell carcinoma
. Cancer 92:3, pages 519-523.
Crossref
Crossref
Jens Atzpodien, Tatjana Patzelt & Martina Reitz. 2001. Urogenitale Carcinome. Urogenitale Carcinome
179
213
.
ROBERT J. MOTZER & PAUL RUSSO. (2000) SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA. The Journal of Urology, pages 408.
Crossref
Crossref
ROBERT J. MOTZER & PAUL RUSSO. (2000) SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA. Journal of Urology 163:2, pages 408-417.
Crossref
Crossref
PETER NYGREN, KATALIN CSÒKA, ROLF LARSSON, CHRISTER BUSCH, KENNETH WESTER & PER-UNO MALMSTRÖM. (1999) ACTIVITY OF STANDARD AND INVESTIGATIONAL CYTOTOXIC DRUGS IN PRIMARY CULTURES OF TUMOR CELLS FROM PATIENTS WITH KIDNEY AND URINARY BLADDER CARCINOMAS. Journal of Urology 162:6, pages 2200-2204.
Crossref
Crossref
M.D. De Furia. (1997) Paclitaxel (Taxol?): A new natural product with major anticancer activity. Phytomedicine 4:3, pages 273-282.
Crossref
Crossref
P. Reinecke, J. Corvin, H.E. Gabbert & C.D. Gerharz. (1997) Antiproliferative effects of paclitaxel (Taxol?) on human renal clear cell carcinomas in vitro. European Journal of Cancer 33:7, pages 1122-1129.
Crossref
Crossref
Eric K. Rowinsky & Ross C. Donehower. (1995) Paclitaxel (Taxol). New England Journal of Medicine 332:15, pages 1004-1014.
Crossref
Crossref
Robert A. Newman & Dominic Fan. 1995. Alternative Mechanisms of Multidrug Resistance in Cancer. Alternative Mechanisms of Multidrug Resistance in Cancer
153
171
.
J. Verweij, M. Clavel & B. Chevalier. (1994) Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): Not simply two of a kind. Annals of Oncology 5:6, pages 495-505.
Crossref
Crossref
Jim M. Koeller & Robert T. Dorr. (2016) Summary. Annals of Pharmacotherapy 28:5_suppl, pages S31-S34.
Crossref
Crossref
HARRY J. LONG. (1994) Paclitaxel (Taxol): A Novel Anticancer Chemotherapeutic Drug. Mayo Clinic Proceedings 69:4, pages 341-345.
Crossref
Crossref
W.C. Mertens, E.A. Eisenhauer, J. Jolivet, S. Ernst, M. Moore & A. Muldal. (1994) Docetaxel in advanced renal carcinoma. Annals of Oncology 5:2, pages 185-187.
Crossref
Crossref
David R. Kohler & Barry R. Goldspiel. (2012) Paclitaxel (Taxol). Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 14:1, pages 3-34.
Crossref
Crossref
H.-J. Guchelaar, C.H.H. Ten Napel, E.G.E. de Vries & N.H. Mulder. (1994) Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: A review. Clinical Oncology 6:1, pages 40-48.
Crossref
Crossref
Robin Foa, Larry Norton & Andrew D. Seidman. (1994) Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. International Journal of Clinical & Laboratory Research 24:1, pages 6-14.
Crossref
Crossref
Alan Yagoda, Daniel Petrylak & Seth Thompson. (1993) CYTOTOXIC CHEMOTHERAPY FOR ADVANCED RENAL CELL CARCINOMA. Urologic Clinics of North America 20:2, pages 303-321.
Crossref
Crossref
Avi I. Einzig, Peter H. Wiernik & Edward L. Schwartz. 1991. New Drugs, Concepts and Results in Cancer Chemotherapy. New Drugs, Concepts and Results in Cancer Chemotherapy
89
100
.
Gerd Staehler & Sigmund PomerS. Pomer. 1997. Nierentumoren. Nierentumoren
195
250
.